NIH awards $2M grant for oral mucositis treatment
Biotech firm Synedgen has been awarded a $1.96 million phase II Small Business Innovation Research grant by the National Institutes of Health (NIH) to accelerate the development of Synedgen’s proprietary oral disease treatments. Under this two-year effort, which begins April 1, Synedgen will accelerate the development of Regenasyn, a topical treatment for oral mucositis that both prevents infection and improves healing, the company said. “Severe oral mucositis is the leading

